MedTrace Logo

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

NCT01384747 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2018-06-20

No results posted yet for this study

Summary

* Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions.
* Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions.
* Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.

Conditions

Interventions

DRUG

Fimasartan

60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)

DRUG

Placebo

60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)

Sponsors & Collaborators

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Seung-Jung Park

    lead OTHER

Principal Investigators

  • Seung-Jung Park, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01384747 on ClinicalTrials.gov